TITLE

The co-occurrence of genetic variants in the *TYR* and *OCA2* genes confers susceptibility to albinism

AUTHOR LIST & AFFILIATIONS

David J. Green[1], Vincent Michaud[2,3], Eulalie Lasseaux[2], Claudio Plaisant[2], UK Biobank Eye and Vision Consortium, Tomas Fitzgerald[4], Ewan Birney[4], Graeme C. Black[1,5,#], Benoît Arveiler[2,3,#], Panagiotis I. Sergouniotis[1,4,5,6]

[1] Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

[2] Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.

[3] INSERM U1211, Rare Diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France.

[4] European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Cambridge, UK.

[5] Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

[6] Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

# These authors contributed equally: Graeme C. Black, Benoît Arveiler

Correspondence to

Panagiotis I. Sergouniotis (panagiotis.sergouniotis@manchester.ac.uk).

ABSTRACT

Although rare genetic conditions are mostly caused by DNA sequence alterations that functionally disrupt individual genes, large-scale studies using genome sequencing have started to unmask additional complexity. Understanding how combinations of variants in different genes shape human phenotypes is expected to provide important insights into the clinical and genetic heterogeneity of rare disorders. We used albinism, an archetypal rare condition associated with hypopigmentation, as an exemplar for the study of genetic interactions. We analysed data from the Genomics England 100,000 Genomes Project alongside a cohort of 1,120 individuals with albinism, and investigated the effect of dual heterozygosity for the combination of two established albinism-related variants: *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330]. As each of these changes alone is insufficient to cause disease when present in the heterozygous state, we sought evidence of synergistic effects. We found that, when both variants are present, the probability of receiving a diagnosis of albinism is significantly increased (odds ratio 14.0; 95% confidence interval 6.8 – 26.5; p-value 1.9×10^{-9}). Further analyses in an independent cohort, the UK Biobank, supported this finding and highlighted that heterozygosity for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant combination is associated with statistically significant alterations in visual acuity and central retinal thickness (traits that are considered albinism endophenotypes). The approach discussed in this report opens up new avenues for the investigation of oligogenic patterns in apparently Mendelian disorders.

KEYWORDS: epistasis, digenic, oligogenic, bi-locus, genetic interaction

MAIN TEXT

INTRODUCTION

An individual affected by a condition that appears to segregate as a Mendelian trait, would be expected to carry large-effect genetic variation in a single gene/locus. However, for a significant proportion of affected probands, single-gene-centric genomic analyses fail to identify a clear genetic diagnosis.[1-6] Although this diagnostic and knowledge gap is, to a degree, due to imperfect phenotyping, sequencing or annotation, other factors may be contributing. There is for example growing evidence supporting the hypothesis that many apparently Mendelian phenotypes are caused by the interaction of multiple variants in more than one locus.[7-11] Uncovering such genetic interactions has the potential to provide insights not only into disease mechanisms and diagnostics but also into phenomena like incomplete penetrance and variable expressivity.[12-14]

There are many patterns through which genetic changes in more than one gene can synergistically shape a phenotype. A simple scenario, would involve two heterozygous variants in two distinct loci cooperating to mediate disease (when each individual variant in isolation fails to explain the clinical presentation). Only a small number of cases with this specific form of digenic inheritance have been described[15-17], the majority detected through qualitative approaches involving variant segregation analyses in a small number of families. In these cases, interaction-based models have generally been used to provide a post hoc explanation of the observed phenomena. By contrast, we describe a quantitative, case-control approach that allows obtaining statistical evidence of digenic patterns. We focused on specific genotypes in the *TYR* and *OCA2* genes; biallelic variants in each of these two genes

are associated with albinism, a clinically and genetically heterogeneous group of conditions characterised by reduced levels of melanin pigment. Key features of albinism include visual abnormalities and under-development of the central retina (*i.e.* the fovea); skin and/or hair hypopigmentation may also be present.[18] Building on recent work[19-22], we aimed to advance our understanding of the genetic complexity of this rare disorder.

RESULTS & DISCUSSION

A cohort of 1,015 people with albinism underwent testing of ≤19 albinism-related genes; these individuals were not known to be related and had predominantly European-like ancestries (Supplementary Data 1). A further 105 probands with albinism were identified in the Genomics England 100,000 Genomes Project dataset.[23] A “control” cohort of 29,451 unrelated individuals that had no recorded diagnosis or features of albinism was also identified in this resource (Fig.1, Supplementary Table 1, Methods).



Figure 1. Outline of the case-control study design.

A case-control analysis was performed to gain insights into the role of genotypes involving dual heterozygosity for *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330] in albinism. These two missense changes were selected as they are the commonest albinism-related variants in European-like populations.

The majority of participants in the "case" cohort (1,015/1,120) were identified through the database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. All these probands had at least one key ocular feature of albinism, *i.e.* nystagmus or prominent foveal hypoplasia. The remaining 105/1,120 cases were identified through the Genomics England 100,000 Genomes Project dataset and had a diagnosis of albinism or partial/ocular albinism. The "control" cohort included 29,451 unrelated individuals from the Genomics England 100,000 Genomes Project dataset, none of whom had a recorded diagnosis of albinism.

To reduce the likelihood of obtaining spurious signals due to population stratification effects or due to the presence of albinism-related variants other than the two studied changes, we focused only on individuals who: (i) were projected to have European-like ancestries; (ii) did not have a genotype in keeping with a molecular diagnosis of albinism; (iii) were not heterozygous for a pathogenic or a likely pathogenic variant in *TYR* or *OCA2* (excluding *TYR*:c.1205G>A and *OCA2*:c.1327G>A). The following two covariates were used: sex and number of common albinism-associated alleles, *i.e.* DNA sequence alterations in the genomic locations corresponding to *TYR*:c.−301C>T [rs4547091] and *TYR*:c.575C>A (p.Ser192Tyr) [rs1042602]. These two variants have been previously shown to modify the effect of *TYR*:c.1205G>A which is a common missense change that can act as a "hypomorphic" variant.[19-21]

To assess the robustness of the findings we performed additional analyses in subsets of the cohort. Validation studies in an independent cohort (UK Biobank) were also conducted.

100K_GP, Genomics England 100,000 Genomes Project; HGMD, Human Gene Mutation Database v2021.2; het, heterozygous; UKB, UK Biobank. *TYR* and *OCA2* variant numbering was based on the transcripts with the following identifiers: NM_000372.5/ENST00000263321.6. and NM_000275.3/ENST00000354638.8.

Searching for genetic elements underlying digenic traits may be carried out at the level of genes, genotypes or DNA variants. It is noted that a given pair of DNA variants comprises up to nine pairs of genotypes while a given gene may contain a large number of variants. Each of these search strategies has inherent advantages and pitfalls.[24] We opted for a genotype-based approach that offers a high level of precision and is more likely to provide insights that can be used for clinical genome interpretation.

Our genotype-based analysis focused on two prevalent albinism-related changes, *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330]. We hypothesised that when these two missense variants are both present in the heterozygous state ("dual heterozygosity"), their interaction is driving the pathology observed in albinism. Notably, both these changes have been shown to reduce the activity of their respective protein products *in vitro*.[25-29] Further, previous studies have pointed to a functional interaction between the TYR and OCA2

121 proteins: the latter has a role in the pH regulation of the melanosome which, in turn,
122 can affect the catalytic activity of the former (*i.e.* tyrosinase, the rate-limiting enzyme
123 for the synthesis of melanin in the melanosomes of retinal pigment epithelia and
124 melanocytes).[18,30] Both *TYR*:c.1205G>A and *OCA2*:c.1327G>A have been
125 implicated in albinism when *in trans* with pathogenic changes in the same gene.[21,31]
126 Also, multiple associations have been recorded for these two variants including with
127 skin/hair pigmentation and skin cancer.[32] It is noted that these two changes were
128 chosen as they are the two commonest albinism-related variants in populations of
129 European-like ancestries, a feature that can help mitigate potential issues with
130 statistical power. It is also highlighted that the minor allele frequencies of the
131 *TYR*:c.1205G>A and *OCA2*:c.1327G>A changes in European populations are 27%
132 and 0.3% respectively (Non-Finnish European subset of the Genome Aggregation
133 Database [gnomAD] v2.1.1).[33] The particularly common *TYR*:c.1205G>A change
134 has been associated with incomplete penetrance (and variable expressivity), and
135 previous studies have pointed to the potential for other *TYR* variants to modify its
136 effect.[19-21,25,34-36]
137
138 We used Firth regression analysis[37,38] to study how dual heterozygosity for
139 *TYR*:c.1205G>A and *OCA2*:c.1327G>A affects the probability of receiving a
140 diagnosis of albinism ("risk of albinism"). This logistic regression approach has been
141 designed to handle small, imbalanced datasets (which are common in studies of rare
142 conditions) and allows for adjustment of key covariates (which is not possible in
143 contingency table methods) (Fig.1). To increase the genetic similarity[39] between the
144 compared cohorts (cases and controls) and to reduce the impact of albinism-related
145 variants other than the two studied changes (*TYR*:c.1205G>A and

146 *OCA2*:c.1327G>A), we excluded from our analysis individuals that: (i) did not have
147 European-like ancestries, (ii) were found to have genotypes in keeping with a
148 molecular diagnosis of albinism, (iii) carried pathogenic or likely pathogenic variants
149 in the *TYR* or *OCA2* gene (with the exception of *TYR*:c.1205G>A and
150 *OCA2*:c.1327G>A). The resulting case and control cohorts included 205 and 20,350
151 individuals respectively. These were used to perform case-control comparisons
152 between the following genotype groups:

153 - *group A* (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
154 - *group B* (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and
155 homozygous for *OCA2*:c.1327=.
156 - *group C* (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and
157 heterozygous for *OCA2*:c.1327G>A.
158 - *group D* (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and
159 *OCA2*:c.1327G>A variant combination.

160 These groups correspond to different levels of dysfunction of the OCA2 and TYR
161 molecules and the findings of the regression analysis revealed a synergistic
162 potentiation of the changes at the two loci (Fig.2, Supplementary Figure 1a and
163 Supplementary Table 2). The point estimate for the odds of receiving a diagnosis of
164 albinism in individuals who are heterozygous for the *TYR*:c.1205G>A and
165 *OCA2*:c.1327G>A variant combination was 14.0 (the 95% confidence interval was
166 6.8 – 26.5 and the p-value was 1.9×10^{-9}).

167



Figure 2. The combination of the *TYR*:c.1205G>A (p.Arg402Gln) and *OCA2*:c.1327G>A (p.Val443Ile) variants in a dual heterozygous state confers susceptibility to albinism.

The probability of receiving a diagnosis of albinism (*i.e.* the risk of albinism) was calculated for the following genotype groups:

- ***group A*** (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
- ***group B*** (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and homozygous for *OCA2*:c.1327=
- ***group C*** (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and heterozygous for *OCA2*:c.1327G>A
- ***group D*** (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant combination.

A $\log_{10}$ scale is used. The circle in the middle of each horizontal line (95% confidence interval) represents the point estimate of each odds ratio. Group A was used as the reference group to which all other groups were compared using Firth regression analysis (*i.e.* the odds ratio for this group was fixed at 1). Further information including numerical data can be found in Supplementary Table 2.

To increase confidence in these observations, we performed additional analyses in an independent cohort, the UK Biobank.[40] We found that UK Biobank volunteers who were heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant combination had not only a higher chance of receiving a diagnosis of albinism (OR>3.1, p-value=0.003) but also had, on average, slightly worse visual acuity and

174 marginally thicker central retina (the respective Kruskal-Wallis p-values were 2.5 x
175 10^{-6} and 6.3 x 10^{-5}; Fig.3 and Supplementary Tables 3 and 4). It is noted that visual
176 acuity and central retinal thickness are quantitative endophenotypes of albinism and
177 these findings suggest that the studied *TYR*/*OCA2* variant combination is both
178 contributing to the genetic architecture of albinism and having a role in the
179 development of the visual system in individuals from the general population.
180



Figure 3. The combination of the *TYR*:c.1205G>A (p.Arg402Gln) and *OCA2*:c.1327G>A (p.Val443Ile) variants in a dual heterozygous state is associated with (a) a higher probability of receiving an albinism diagnosis (*i.e.* a higher risk of albinism), (b) lower visual acuity and (c) increased central retinal thickness in UK Biobank participants.

The following genotype groups were studied:

- ***group A*** (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
- ***group B*** (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and homozygous for *OCA2*:c.1327=
- ***group C*** (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and heterozygous for *OCA2*:c.1327G>A
- ***group D*** (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant combination.

It is noted that individuals with albinism tend to have reduced visual acuity (*i.e.* higher LogMAR value than 0.2) and increased central retinal thickness (due to underdevelopment of the fovea). Further information including numerical data can be found in Supplementary Tables 3 and 4.

181

182 We provide evidence that the *TYR*:c.1205G>A and *OCA2*:c.1327G>A changes
183 appear to have a joint effect when each is encountered in the heterozygous state.
184 However, the interpretation of this variant combination in clinical diagnostic settings
185 should be approached cautiously. Although the detected effect size (odds ratio) is
186 significant, it would be more in keeping with a predisposing[41] rather than a
187 pathogenic[42] genotype. Further, while it is tempting to view our observations as an
188 example of a digenic pattern, this would have reductionist connotations; interactions
189 are ubiquitous in nature and we expect that increased sample sizes will elucidate
190 longer "chains" of interconnected genetic variation. It is thus plausible that the effect
191 size of the studied genotype will increase when further genetic changes that impact
192 on tyrosinase function or melanosome pH are added to the model. Indeed,
193 observations in the presented data already point to this possibility (Supplementary
194 Data 2 and 3).
195
196 One limitation of this study is our inability to match stringently the albinism cases with
197 the unaffected controls, especially in terms of genetic background.[43] Although recent
198 ancestry was considered, our analysis was imperfect as it was not possible to
199 reliably assign genetic ancestry to most albinism cases. We used a combination of
200 orthogonal approaches to evaluate the robustness and generalisability of our
201 findings. First, we used 35 presumed neutral single-nucleotide variants to calculate
202 the genomic inflation factor lambda (λGC)[44,45]; the λ_{median} was found to be 1.04, in
203 keeping with limited confounding by ancestry (Supplementary Table 5).
204 Subsequently, we performed a targeted secondary analysis using only Genomics
205 England 100,000 Genomes Project data which allowed us to study case and control
206 groups of high genetic similarity. The results supported our key findings and

207 increased confidence in the validity of the detected associations (Supplementary
208 Fig.1b and Supplementary Table 6). Another potential caveat is that the detected
209 signal in dual heterozygotes for *TYR*:c.1205G>A and *OCA2*:c.1327G>A could, to a
210 degree, be driven by undetected pathogenic variation in either *TYR* or *OCA2*. This
211 cannot be excluded despite the fact that medical-grade genetic analyses were
212 undertaken. It can be argued however that significant confounding is unlikely
213 especially given that the effect of dual heterozygosity for *TYR*:c.1205G>A and
214 *OCA2*:c.1327G>A appears to be greater than that of genotypes involving
215 heterozygosity for either *TYR*:c.1205G>A or *OCA2*:c.1327G>A alone
216 (Supplementary Table 2, 3, 6 and 7).
217
218 In conclusion, we have shown that dual heterozygosity for a *TYR* and an *OCA2*
219 variant confers susceptibility to albinism. Shedding light into this and other variant
220 interactions is expected to increase our understanding of the pathways and cellular
221 processes affected in albinism. Notably, the concepts discussed herein are likely to
222 be relevant to other rare disorders, and systems-based approaches using biological
223 modules are expected to narrow the molecular diagnostic gap. Future work will focus
224 on increasing sample sizes, embracing more diverse populations and searching for
225 high-order interactions by considering more than two variants at a time.
226

227 **METHODS**

228

229 **Cohort characteristics and genotyping**

230 *University Hospital of Bordeaux albinism cohort*

231 Individuals with albinism were identified through the database of the University Hospital of Bordeaux
232 Molecular Genetics Laboratory, France. This is a national reference laboratory that has been
233 performing genetic testing for albinism since 2003 and has been receiving samples from individuals
234 predominantly based in France (or French-administered overseas territories).

235

236 Information on the dermatological and ophthalmological phenotypes was available for all affected
237 individuals, and each of these cases had at least one of the key ocular features of albinism, *i.e.*
238 infantile nystagmus or absence of a foveal pit (prominent foveal hypoplasia). No pre-screening based
239 on genotype was undertaken other than selecting individuals in whom position c.-301 of *TYR* was
240 sequenced. Only individuals who were not knowingly related were included.

241

242 Genetic testing, bioinformatic analyses, and variant interpretation were performed as previously
243 described.[20,21] Briefly, most participants had gene-panel testing of ≤19 genes associated with albinism
244 (*TYR*, *OCA2*, *TYRP1*, *SLC45A2*, *SLC24A5*, *C10ORF11*, *GPR143*, *HPS 1* to 10, *LYST*, *SLC38A8*)
245 using IonTorrent platforms. High-resolution array-CGH (comparative genomic hybridization) was used
246 to detect copy number variants in these genes. All genetic changes of interest were confirmed with an
247 alternative method (e.g. Sanger sequencing or quantitative PCR). Clinical interpretation of variants
248 was performed using criteria consistent with the 2015 American College of Medical Genetics and
249 Genomics (ACMG) best practice guidelines.[42] It is noted that genetic findings in this cohort have been
250 partly reported in previous publications from our group.[19,22]

251

252 Due to the limited number of genomic locations screened in this cohort, it was not possible to reliably
253 assess genetic ancestry and to "objectively" assign individuals to genetic ancestry groups. Attempting
254 to mitigate this, we processed available data on self-identified ethnicity that were collected through
255 questionnaires. Responses were inspected and stratification into five broad continental groups
256 (European, African, Admixed American, East Asian, South Asian) was performed.

257
258
259

260 *Genomics England 100,000 Genomes Project cohort*

261 Clinical and genomic data from the Genomics England 100,000 Genomes Project were accessed
262 through a secure Research Environment that is available to registered users. This dataset was
263 collected as part of a national genome sequencing initiative.[46] Enrolment was coordinated by
264 Genomics England Limited, and participants were recruited mainly at National Health Service (NHS)
265 Hospitals in the UK.[23] Clinical information was recorded in Human Phenotype Ontology (HPO)[47] terms
266 and International Classification of Diseases (ICD) codes. Genome sequencing was performed in DNA
267 samples from ≥78,195 individuals using Illumina HiSeq X systems (150 base-pair paired-end format).
268 Reads were aligned using the iSAAC Aligner v03.16.02.19 and small variants were called using
269 Starling v2.4.7.[48] Structural variants and long indel (>50bp) calling was performed with Manta v0.28.0,
270 and copy number variants (CNVs) were called with Canvas v1.3.1.[49,50] Aggregation of single-sample
271 gVCFs was performed using the Illumina software gVCF genotyper v2019.02.29;
272 normalisation/decomposition was implemented by vt v0.57721[51]. The multi-sample VCF was then split
273 into 1,371 roughly equal chunks to allow faster processing and the loci of interest were queried using
274 bcftools v1.9[52] (see https://research-help.genomicsengland.co.uk/display/GERE/ for further
275 information). Only variants that passed standard quality control criteria were processed (including the
276 criteria discussed in https://re-docs.genomicsengland.co.uk/site_qc/ and criteria analogous to those
277 outlined in https://re-docs.genomicsengland.co.uk/somatic_sv/#note-on-variant-calling). In addition,
278 we filtered out genotypes with: genotype score <20; read depth <10; allele balance <0.2 and >0.8 for
279 heterozygotes; allele balance >0.1 or <0.9 for homozygotes (reference and alternate, respectively).
280 Genomic annotation was performed using Ensembl VEP[53]. Variants with a "total" minor allele
281 frequency (MAF) <1% in the Genome Aggregation Database (gnomAD v2.1.1)[33] and a "disease-
282 causing" (DM) label in HGMD v2021.2[54] were flagged (and are hitherto referred to as "HGMD-listed
283 variants"). In depth manual curation of all detected rare (*i.e.* MAF < 1%) variants in *TYR* and *OCA2*
284 was undertaken and these changes were classified according to the 2015 American College of
285 Medical Genetics and Genomics (ACMG) best practice guidelines.[42]
286
287 Ancestry inference was performed in the Genomics England 100,000 Genomes Project cohort using
288 principal component analysis. Data from the 1000 genomes project (phase 3) dataset were used and
289 five broad super-populations were projected (European, African, Admixed American, East Asian,

290 South Asian) (further information on this can be found online at https://research-
291 help.genomicsengland.co.uk/display/GERE/Ancestry+inference).
292
293 We focused on a pre-determined subset of the Genomics England 100,000 Genomes Project dataset
294 that includes only unrelated probands (n=29,556). Of these, 105 had a diagnosis of albinism, *i.e.* the
295 ICD-10 term "Albinism" [E70.3] and/or the HPO terms "Albinism" [HP:0001022], "Partial albinism"
296 [HP:0007443] or "Ocular albinism" [HP:0001107] were assigned. Together with the University Hospital
297 of Bordeaux cases, these 105 probands formed the "case" cohort. The remaining 29,451 probands
298 had no recorded diagnosis or phenotypic features of albinism and formed the "control" cohort. We
299 note that comprehensive ophthalmic phenotyping was not routinely undertaken in Genomics England
300 100,000 Genomes Project participants. We cannot therefore be certain that a small number of
301 individuals with mild/subclinical forms of albinism are not included in the control cohort.
302
303
304 **Case-control analysis to estimate the probability of an albinism diagnosis**
305 The effect of dual heterozygosity for *TYR:*c.1205G>A (p.Arg402Gln) [rs1126809] and
306 *OCA2:*c.1327G>A (p.Val443Ile) [rs74653330] on the probability of receiving a diagnosis of albinism
307 (*i.e.* the albinism risk) was estimated using data from the University Hospital of Bordeaux albinism
308 cohort and the Genomics England 100,000 Genomes Project dataset. A case-control analysis of a
309 binary trait (presence/absence of albinism) was conducted assuming a recessive model. Logistic
310 regression using the Firth bias reduction method[37,38] was utilised (as implemented in "logistf" R
311 package). The following parameters were set:
312 • inclusion criteria: the analysis was conducted only on study subjects who: (i) were projected to
313 have European-like ancestries, (ii) were not found to have genotypes in keeping with a molecular
314 diagnosis of albinism, (iii) carried no pathogenic or likely pathogenic variants in the *TYR* or *OCA2*
315 gene (with the exception of the two studied changes *TYR*:c.1205G>A and *OCA2*:c.1327G>A).
316 • covariates: sex; number of common albinism-associated alleles (see relevant sub-section below).
317
318 *Ancestry*: To increase the genetic similarity between the studied case and control cohorts, we focused
319 on individuals who were likely to fall within the same broad ancestral group. It is highlighted though
320 that the utilised approach was imperfect as it was not possible to objectively determine genetic
321 ancestry in individuals from the University Hospital of Bordeaux albinism cohort (as mentioned above,

322 self-identified ethnicity was instead used as a surrogate). Confounding by ancestry (*i.e.* population
323 stratification) is therefore a possibility.[39] We attempted to quantify this by calculating the genomic
324 inflation factor lambda (λGC). A total of 35 single-nucleotide variants were selected using a previously
325 described approach (see Supplementary Table 5 and [18]). Case-control comparisons were then made
326 for each of these 35 λGC markers using Firth regression analysis. The resulting test statistics were
327 used to calculate the median value of λGC.[18]
328
329 *Albinism-related genotypes:* To reduce the likelihood of obtaining spurious results due to the impact of
330 albinism-related variants other than the two studied changes (*TYR*:c.1205G>A and
331 *OCA2*:c.1327G>A), we excluded individuals who carried genotypes consistent with a molecular
332 diagnosis of albinism. This included study subjects with:
333 • homozygous pathogenic or likely pathogenic HGMD-listed variants in autosomal albinism-related
334 genes *(TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10ORF11, HPS 1* to *10, LYST, SLC38A8*),
335 • presumed biallelic pathogenic or likely pathogenic HGMD-listed variants in autosomal albinism-
336 related genes *(TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10ORF11, HPS 1* to *10, LYST,*
337 *SLC38A8*),
338 • hemizygous pathogenic or likely pathogenic HGMD-listed variants in *GPR143* or *FRMD7,*
339 • the *TYR* c.[-301C;575C>A;1205G>A] or *TYR* c.[-301C;575C;1205G>A] albinism-related
340 haplotype[19] in homozygous state
341 • the *TYR* c.[-301C;575C>A;1205G>A] or *TYR* c.[-301C;575C;1205G>A] albinism-related
342 haplotype in heterozygous state plus a heterozygous pathogenic or likely pathogenic variant in
343 *TYR.*
344
345 We also excluded from our analysis individuals who were found to carry pathogenic or likely
346 pathogenic variants in the *TYR* or *OCA2* gene (in heterozygous state). Small scale genetic changes
347 (with the exception of *TYR*:c.1205G>A and *OCA2*:c.1327G>A), copy number and structural variants
348 were factored in.
349
350 *Common albinism-associated alleles:* The effect of one of the studied changes (*TYR* c.1205G>A) has
351 been previously shown to be modified by the following two variants[19-21,25,34-36] which have been added
352 as a covariate to the regression model:

353 • *TYR* c.-301C>T [rs4547091], located in the *TYR* promoter; the derived, non-ancestral allele c.-301C
354 (or c.-301=) has a MAF of ~60% in non-Finnish European (NFE) populations in the Genome
355 Aggregation Database (gnomAD v2.1.1)[33];
356 • *TYR* c.575C>A (p.Ser192Tyr) [rs1042602], which has a MAF of ~36% in gnomAD NFE populations.

357 It is highlighted that the *TYR* c.-301= and the *TYR* c.575C>A (p.Ser192Tyr) alleles are frequently found
358 in linkage disequilibrium so the presence of the latter would, in most cases, suggest the presence of
359 the former on the same haplotype.
360
361 *Case-control comparisons between TYR/OCA2 genotype groups*: Our primary analysis focused on
362 performing case-control comparisons between groups of genotypes that include different alleles at
363 positions *TYR*:c.1205 and *OCA2*:c.1327. These groups were:
364 • group A (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
365 • group B (single TYR heterozygote group): heterozygous for *TYR*:c.1205G>A and homozygous for
366 *OCA2*:c.1327=.
367 • group C (single OCA2 heterozygote group): homozygous for *TYR*:c.1205G= and heterozygous for
368 *OCA2*:c.1327G>A.
369 • group D (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A
370 variant combination.
371 Analyses were also conducted in individuals who were found to be homozygous for *TYR*:c.1205G>A
372 (but are considered unsolved, *i.e.* they do not carry the *TYR* c.575C>A or the *TYR* c.-301= variant in
373 the homozygous state); these were split into two groups:
374 • *group E:* homozygous for *TYR*:c.1205G>A and *OCA2*:c.1327=;
375 • *group F:* homozygous for *TYR*:c.1205G>A and heterozygous for OCA2:c.1327G>A
376
377 Group A was used as the reference group to which all other groups were compared using Firth
378 regression analysis (*i.e.* the odds ratio for this group was fixed at 1).
379
380 The primary analysis focused on a mixed case cohort (including 174 probands from the University
381 Hospital of Bordeaux cohort and 31 cases from the Genomics England 100,000 Genomes Project
382 dataset) and a control cohort from the Genomics England 100,000 Genomes Project dataset (20,350
383 unrelated individuals) (Fig.2; Supplementary Fig.1a; Supplementary Table 2). A secondary analysis

focusing only on individuals from the Genomics England 100,000 Genomes Project dataset (31 cases, 20,350 controls) was also undertaken (Supplementary Fig.1b; Supplementary Table 6).

Replication of findings in the UK Biobank cohort

The effect of dual heterozygosity for *TYR:*c.1205G>A and *OCA2:*c.1327G>A was studied in the UK Biobank. UK Biobank is a biomedical resource containing in-depth genetic and health information from >500,000 individuals from across the UK.[40] A subset of UK Biobank volunteers underwent enhanced phenotyping including visual acuity testing (131,985 individuals) and imaging of the central retina (84,748 individuals)[55]; the latter was obtained using optical coherence tomography (OCT), a non-invasive imaging test that rapidly generates cross-sectional retinal scans at micrometre-resolution.[56,57] All UK Biobank volunteers whose data were analysed as part of this study were imaged using the 3D OCT-1000 Mark II device (Topcon, Japan); the relevant methodology has been previously described.[55] Notably, only 24 UK Biobank participants have been assigned a diagnosis of albinism (data field 41270; ICD-10 term “Albinism” [E70.3]) of which only 7 had visual acuity measurements and none had OCT imaging; 19 additional individuals had a diagnosis of albinism in their primary care record data (resource 591).

Aiming to assess the robustness of the results in the combined University Hospital of Bordeaux and Genomics England 100,000 Genomes Project dataset, we performed case-control analyses in UK Biobank volunteers. First, genotyping array data were used to obtain genotypes for the *TYR:*c.1205G>A variant (data field 22418 including information from the Applied Biosystems UK Biobank Axiom Array containing 825,927 markers). In contrast to this change, the *OCA2:*c.1327G>A variant was not directly captured by the array. However, high-quality (>99.9%) imputation data were available (data field 22828). Only individuals successfully genotyped at both sites were retained.

Firth regression analysis was subsequently used to perform comparisons between genotype groups A-D. Only individuals who were estimated by principal component analysis to have European-like ancestries (data field 22006) were included in this analysis; sex and the number of common albinism-associated alleles were used as covariates (Fig.3a; Supplementary Table 3).

415 Given that reduced visual acuity and increased central retinal thickness (due to underdevelopment of
416 the fovea) are two hallmark features of albinism we investigated the impact of selected *TYR/OCA2*
417 variant combinations on these two quantitative traits.
418
419 We first obtained data on the left LogMAR visual acuity for UK Biobank volunteers (data field 5201,
420 "instance 0" datasets). These visual acuity measurements were then used to compare visual
421 performance between groups of volunteers with selected *TYR/OCA2* genotype combinations
422 (genotype groups A-D). As the obtained distributions deviated from normality, the Kruskal-Wallis test
423 was used. Pair-wise comparisons were performed and the p-values were adjusted using the
424 Benjamini-Hochberg method (Fig.3b; Supplementary Table 4).
425
426 We then obtained central retinal thickness measurements from UK Biobank OCT images using the
427 "macular thickness at the central subfield" data field (27802; defined as the average distance between
428 the hyperreflective bands corresponding to the RPE and the internal limiting membrane (ILM), across
429 the central 1 mm diameter circle of the ETDRS grid) for UK Biobank volunteers.[58] The obtained
430 measurements were subsequently used to compare central retinal thickness between groups of UK
431 Biobank volunteers with selected *TYR/OCA2* genotype combinations (groups A-D). As some of the
432 obtained distributions deviated from normality, the Kruskal-Wallis test was used. Pair-wise
433 comparisons were performed and the p-values were adjusted using the Benjamini-Hochberg method
434 (Fig.3c; Supplementary Table 4).
435
436 It is noted that we opted to perform all UK Biobank analyses on left eye data. This is because, as per
437 study protocol[55], the left eye was tested after the right eye, potentially making the measurements from
438 the left side less prone to artifacts (as the participants were more familiar with the test).
439
440
441 **Additional analysis in the University Hospital of Bordeaux albinism cohort**
442 Further analyses were undertaken using only data from individuals in the University Hospital of
443 Bordeaux albinism cohort. After excluding study subjects who did not report having European-like
444 ancestries, the cohort was split into cases with and cases without a molecular diagnosis of albinism
445 (*i.e.* "solved" and "unsolved"). Individuals without a molecular diagnosis who carried heterozygous
446 pathogenic or likely pathogenic variants in the *TYR* or *OCA2* gene (with the exception of the two

447 studied changes *TYR*:c.1205G>A and *OCA2*:c.1327G>A) were then removed from the unsolved
448 group. The patterns observed in genotype groups A-D were then assessed using both contingency
449 table methods and Firth regression analyses (Supplementary Table 7).
450
451
452 **Ethics approval**
453 Informed consent was obtained from all participants or their parents in the case of minors. The study
454 of individuals from the University Hospital of Bordeaux albinism cohort has been approved by the
455 relevant local ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III,
456 Bordeaux, France). The informed consent process for the Genomics England 100,000 Genomes
457 Project has been approved by the National Research Ethics Service Research Ethics Committee for
458 East of England – Cambridge South Research Ethics Committee. The UK Biobank has received
459 approval from the National Information Governance Board for Health and Social Care and the
460 National Health Service North West Centre for Research Ethics Committee (Ref: 11/NW/0382). All
461 investigations were conducted in accordance with the tenets of the Declaration of Helsinki.
462

DATA AVAILABILITY

The Genomics England 100,000 Genomes Project dataset is available under restricted access through a procedure described at https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-access. The UK Biobank dataset is available under restricted access through a procedure described at http://www.ukbiobank.ac.uk/using-the-resource/. All other data supporting the findings of this study are available within the article (including its Supplementary Information files).

CODE AVAILABILITY

The scripts used to analyse the datasets included in this study are available at https://github.com/davidjohngreen/tyr-oca2.

REFERENCES

1. Boycott, K.M. *et al*. A diagnosis for all rare genetic diseases: The horizon and the next frontiers. *Cell.***177**, 32-37 (2019). doi: 10.1016/j.cell.2019.02.040.
2. Splinter, K. *et al*. Effect of genetic diagnosis on patients with previously undiagnosed disease. *N Engl J Med*. **379**, 2131-2139 (2018). doi: 10.1056/NEJMoa1714458.
3. Posey, J.E. *et al*. Insights into genetics, human biology and disease gleaned from family based genomic studies. *Genet Med*. **21**, 798-812 (2019). doi: 10.1038/s41436-018-0408-7.
4. Zurek, B. *et al*. Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. *Eur J Hum Genet.* **29**, 1325-1331 (2021). doi: 10.1038/s41431-021-00859-0
5. 100,000 Genomes Project Pilot Investigators. 100,000 Genomes Pilot on rare-disease diagnosis in health care - Preliminary report. *N Engl J Med*. **385**, 1868-1880 (2021). doi: 10.1056/NEJMoa2035790.
6. Boycott, K.M. *et al*. Care4Rare Canada: Outcomes from a decade of network science for rare disease gene discovery. *Am J Hum Genet*. **109**, 1947-1959 (2022). doi: 10.1016/j.ajhg.2022.10.002.
7. Schäffer, A.A. Digenic inheritance in medical genetics. *J Med Genet*. **50**, 641-652 (2013). doi: 10.1136/jmedgenet-2013-101713.
8. Katsanis, N. The continuum of causality in human genetic disorders. *Genome Biol*. **17**, 233 (2016). doi: 10.1186/s13059-016-1107-9.
9. Deltas C. Digenic inheritance and genetic modifiers. *Clin Genet*. **93**, 429-438 (2018). doi: 10.1111/cge.13150.
10. Nachtegael, C. *et al*. Scaling up oligogenic diseases research with OLIDA: the Oligogenic Diseases Database. *Database (Oxford).* **2022**, baac023 (2022). doi: 10.1093/database/baac023.
11. Burkard, M. *et al.* Accessory heterozygous mutations in cone photoreceptor CNGA3 exacerbate CNG channel-associated retinopathy. *J Clin Invest*. **128**, 5663-5675 (2018). doi: 10.1172/JCI96098
12. Cooper, D.N., Krawczak, M., Polychronakos, C., Tyler-Smith, C. & Kehrer-Sawatzki, H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. *Hum Genet.* **132**, 1077-1130 (2013). doi: 10.1007/s00439-013-1331-2.
13. Kousi, M. & Katsanis, N. Genetic modifiers and oligogenic inheritance. *Cold Spring Harb Perspect Med*. **5**, a017145 (2015). doi: 10.1101/cshperspect.a017145.
14. Costanzo, M. *et al*. Global genetic networks and the genotype-to-phenotype relationship. *Cell*. **177**, 85-100 (2019). doi: 10.1016/j.cell.2019.01.033.
15. Mukherjee, S. *et al*. Identifying digenic disease genes via machine learning in the Undiagnosed Diseases Network. *Am J Hum Genet.* **108**, 1946-1963 (2021). doi: 10.1016/j.ajhg.2021.08.010.
16. Papadimitriou, S. *et al*. Predicting disease-causing variant combinations. *Proc Natl Acad Sci U S A*. **116**:11878-11887 (2019). doi: 10.1073/pnas.1815601116.
17. Brehm, A. *et al*. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. *J Clin Invest*. **125**, 4196-4211 (2015). doi: 10.1172/JCI81260.
18. Bakker, R. *et al*. The retinal pigmentation pathway in human albinism: Not so black and white. *Prog Retin Eye Res*. **91**, 101091 (2022). doi: 10.1016/j.preteyeres.2022.101091.
19. Michaud, V. *et al*. The contribution of common regulatory and protein-coding TYR variants to the genetic architecture of albinism. *Nat Commun*. **13**, 3939 (2022). doi: 10.1038/s41467-022-31392-3.
20. Campbell, P. *et al*. Clinical and genetic variability in children with partial albinism. *Sci Rep*. **9**, 16576 (2019). doi: 10.1038/s41598-019-51768-8.
21. Monfermé, S. *et al*. Mild form of oculocutaneous albinism type 1: phenotypic analysis of compound heterozygous patients with the R402Q variant of the *TYR* gene. *Br J Ophthalmol*. **103**, 1239-1247 (2019). doi: 10.1136/bjophthalmol-2018-312729
22. Lasseaux, E. *et al*. Molecular characterization of a series of 990 index patients with albinism. *Pigment Cell Melanoma Res*. **31**, 466-474 (2018). doi: 10.1111/pcmr.12688.
23. Caulfield, M. *et al*. The National Genomic Research Library. https://doi.org/10.6084/m9.figshare.4530893.v7 (2017).

24. Okazaki, A. & Ott, J. Machine learning approaches to explore digenic inheritance. *Trends Genet*. **38**, 1013-1018 (2022). doi: 10.1016/j.tig.2022.04.009.
25. Jagirdar, K. *et al*. Molecular analysis of common polymorphisms within the human tyrosinase locus and genetic association with pigmentation traits. *Pigment Cell Melanoma Res*. **27**, 552-564 (2014). doi: 10.1111/pcmr.12253.
26. Dolinska, M.B. *et al*. Oculocutaneous albinism type 1: link between mutations, tyrosinase conformational stability, and enzymatic activity. Pigment Cell Melanoma Res. **30**, 41-52 (2017). doi: 10.1111/pcmr.12546.
27. Sviderskaya, E.V. *et al*. Complementation of hypopigmentation in p-mutant (pink-eyed dilution) mouse melanocytes by normal human P cDNA, and defective complementation by OCA2 mutant sequences. *J Invest Dermatol*. **108**, 30-34 (1997). doi: 10.1111/1523-1747.ep12285621
28. Bellono, N.W., Escobar, I.E., Lefkovith, A.J., Marks, M.S. & Oancea, E. An intracellular anion channel critical for pigmentation. *Elife*. **3**, e04543 (2014). doi: 10.7554/eLife.04543.
29. Bellono, N.W., Escobar, I.E. & Oancea, E. A melanosomal two-pore sodium channel regulates pigmentation. *Sci Rep*. **6**, 26570 (2016). doi: 10.1038/srep26570.
30. Pavan W.J. & Sturm, R.A. The genetics of human skin and hair pigmentation. *Annu Rev Genomics Hum Genet*. **20**, 41-72 (2019). doi: 10.1146/annurev-genom-083118-015230.
31. Landrum, M.J. *et al*. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res.* **46**, D1062-D1067 (2018). doi: 10.1093/nar/gkx1153. [accessions VCV000003779.25 & VCV000000955.52].
32. Buniello, A. *et al*. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005-D1012 (2019). doi: 10.1093/nar/gky1120. [entries for rs1126809 and rs74653330]
33. Karczewski, K.J. *et al*. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. **581**, 434-443 (2020). doi: 10.1038/s41586-020-2308-7. [entries for 11-89017961-G-A (GRCh37) and 15-28228553-C-T (GRCh37)]
34. Loftus, S.K. *et al*. Haplotype-based analysis resolves missing heritability in oculocutaneous albinism type 1B. *Am J Hum Genet*. **S0002-9297**, 00169-6 (2023). doi: 10.1016/j.ajhg.2023.05.012.
35. Lin, S., *et al*. Evidence that the Ser192Tyr/Arg402Gln in *cis* Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B). *NPJ Genom Med*. **7**, 2 (2022). doi: 10.1038/s41525-021-00275-9.
36. Grønskov, K. *et al*. A pathogenic haplotype, common in Europeans, causes autosomal recessive albinism and uncovers missing heritability in OCA1. *Sci Rep.* **9**, 645 (2019). doi: 10.1038/s41598-018-37272-5.
37. Heinze, G. & Schemper, M. A solution to the problem of separation in logistic regression. *Stat Med.* **21**, 2409-19 (2002). doi: 10.1002/sim.1047.
38. Firth, D. Bias reduction of maximum likelihood estimates. *Biometrika*. **80**, 27-38 (1993). doi: 10.1093/biomet/80.1.27
39. Marchini, J., Cardon, L.R., Phillips, M.S. & Donnelly, P. The effects of human population structure on large genetic association studies. *Nat Genet.* **36**, 512–517 (2004). doi: 10.1038/ng1337
40. Bycroft, C. *et al*. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. **562**, 203-209 (2018). doi: 10.1038/s41586-018-0579-z.
41. Masson, E. *et al*. Expanding ACMG variant classification guidelines into a general framework. *Hum Genomics*. **16**, 31 (2022). doi: 10.1186/s40246-022-00407-x.
42. Richards, S. *et al*. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. **17**, 405-424 (2015). doi: 10.1038/gim.2015.30.
43. Freedman, M.L. *et al*. Assessing the impact of population stratification on genetic association studies. *Nat Genet*. **36**, 388-93 (2004). doi: 10.1038/ng1333.
44. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics*. **55**, 997-1004 (1999). doi: 10.1111/j.0006-341x.1999.00997.x
45. Dadd, T., Weale, M.E. & Lewis, C.M. A critical evaluation of genomic control methods for genetic association studies. *Genet Epidemiol*. **33**, 290-298 (2009). doi: 10.1002/gepi.20379.
46. Turnbull, C. *et al.* The 100,000 Genomes Project: bringing whole genome sequencing to the NHS. *BMJ* **361**, 1687 (2018). doi: 10.1136/bmj.k1687

47. Köhler, S. *et al.* The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* **49**, D1207–D1217 (2021). doi: 10.1093/nar/gkaa1043
48. Raczy, C. *et al.* Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms. *Bioinformatics* **29**, 2041–2043 (2013). doi: 10.1093/bioinformatics/btt314.
49. Chen, X., *et al.* Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. *Bioinformatics* **32**, 1220-1222 (2016). doi: 10.1093/bioinformatics/btv710.
50. Roller, E., Ivakhno, S., Lee, S., Royce, T. & Tanner, S. Canvas: versatile and scalable detection of copy number variants. *Bioinformatics* **32**, 2375-2377 (2016). doi: 10.1093/bioinformatics/btw163.
51. Tan, A., Abecasis, G.R. & Kang, H.M. Unified representation of genetic variants. *Bioinformatics* **31**, 2202–2204 (2015). doi: 10.1093/bioinformatics/btv112
52. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008 (2021).
53. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, (2016). doi: 10.1186/s13059-016-0974-4
54. Stenson, P.D. *et al*. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. *Hum Genet*. **139**, 1197-1207 (2020). doi: 10.1007/s00439-020-02199-3.
55. Chua, S.Y.L., *et al.* Cohort profile: design and methods in the eye and vision consortium of UK Biobank. *BMJ Open* **9**, e025077 (2019).
56. Bouma, B.E. *et al*. Optical coherence tomography. *Nat Rev Methods Primers*. **2,** 79 (2022). doi: 10.1038/s43586-022-00162-2.
57. Drexler, W. & Fujimoto, J.G. State-of-the-art retinal optical coherence tomography. *Prog Retin Eye Res*. **27**, 45–88 (2008). doi: 10.1016/j.preteyeres.2007.07.005
58. Currant, H. *et al*. Genetic variation affects morphological retinal phenotypes extracted from UK Biobank optical coherence tomography images. *PLoS Genet*. **17**, e1009497 (2021). doi: 10.1371/journal.pgen.1009497

ACKNOWLEDGEMENTS

We acknowledge the following sources of funding: the Wellcome Trust (224643/Z/21/Z, Clinical Research Career Development Fellowship to P.I.S.; 200990/Z/16/Z, Transforming Genetic Medicine Initiative to G.C.B.); the UK National Institute for Health Research (NIHR) Clinical Lecturer Programme (CL-2017-06-001 to P.I.S.); Retina UK and Fight for Sight (GR586, RP Genome Project - UK Inherited Retinal Disease Consortium to G.C.B.); Christopher Green (D.J.G.); the French Albinism Association (Genespoir) and the French National Research Agency (Agence Nationale de la Recherche; ANR-21-CE17-0041-01 to B.A.).

The UK Biobank Eye and Vision Consortium is supported by funding from the NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of

641 Ophthalmology, the Alcon Foundation and the Desmond Foundation. The complete
642 list of members of this Consortium can be found in the Supplementary Information
643
644 This research was made possible through access to the data and findings generated
645 by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by
646 Genomics England Limited (a wholly owned company of the Department of Health
647 and Social Care). The 100,000 Genomes Project is funded by the NIHR and NHS
648 England. The Wellcome Trust, Cancer Research UK and the Medical Research
649 Council have also funded research infrastructure. The 100,000 Genomes Project
650 uses data provided by patients and collected by the National Health Service (NHS)
651 as part of their care and support. We acknowledge the contribution of the Genomics
652 England Research Consortium to the 100,000 Genomes Project. The complete list of
653 members of this Consortium can be found in the Supplementary Information.
654
655 Lastly, we acknowledge the help of Cécile Courdier at the University Hospital of
656 Bordeaux Molecular Genetics Laboratory, Sophie Javerzat at the University of
657 Bordeaux, Dave Gerrard at the University of Manchester, and Claire Hardcastle,
658 Chris Campbell, Steph Barton and Simon Ramsden at the North West of England
659 Genomic Laboratory Hub.

AUTHOR CONTRIBUTIONS STATEMENT

P.I.S. conceived and designed the experiments. The UK Biobank Eye and Vision Consortium, T.F., E.B., B.A., G.C.B. and P.I.S provided datasets and analytical tools. D.J.G., V.M., E.L., C.P., T.F., B.A. and P.I.S. analysed the data. P.I.S. wrote the manuscript with support from D.J.G. All authors critically revised and approved the manuscript.

G.C.B. and B.A. contributed equally to this work.

COMPETING INTERESTS STATEMENT

E.B. is a paid consultant and equity holder of Oxford Nanopore, a paid consultant to Dovetail, and a non-executive director of Genomics England, a limited company wholly owned by the UK Department of Health and Social Care. All other authors declare no competing interests.



validation:

- analysis repeated in cases and controls from the 100K_GP only
- analysis repeated and expanded in an independent cohort (UK Biobank)

genotype		
TYR: **c.1205G>A (p.Arg402Gln)**	***OCA2*:** **c.1327G>A (p.Val443Ile)**	**group**
GG	GG	***A***
AG	GG	***B***
GG	AG	***C***
AG	AG	***D***




genotype
TYR: c.1205G>A (p.Arg402Gln)
OCA2: c.1327G>A (p.Val443Ile)
group
GG GG A
AG GG B
GG AG C
AG AG D
a
probability of receiving a diagnosis of albinism (odds ratio, log10)
0.1
1
10
100
b
left visual acuity (LogMAR)
0.0
0.5
1.0
c
left central retinal thickness (µm)
200
300
400
500